Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
SALT LAKE CITY, May 31, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four Seasons Hotel in Chicago, Illinois.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
